Royal Bank of Canada Boosts Humana (NYSE:HUM) Price Target to $544.00

Humana (NYSE:HUMGet Rating) had its target price hoisted by Royal Bank of Canada from $541.00 to $544.00 in a research report report published on Tuesday morning, The Fly reports. They currently have an outperform rating on the insurance provider’s stock.

Other research analysts have also issued reports about the company. SVB Leerink upped their price target on Humana from $535.00 to $540.00 and gave the stock an outperform rating in a report on Thursday, July 28th. Oppenheimer raised their price target on shares of Humana from $520.00 to $550.00 and gave the stock an outperform rating in a research report on Friday, September 16th. Loop Capital started coverage on shares of Humana in a research report on Thursday, June 16th. They set a buy rating and a $510.00 price objective for the company. Deutsche Bank Aktiengesellschaft lifted their target price on Humana from $450.00 to $514.00 in a research report on Thursday, July 28th. Finally, Sanford C. Bernstein began coverage on Humana in a research report on Thursday, May 26th. They issued a market perform rating and a $506.00 price objective for the company. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from, the stock presently has an average rating of Moderate Buy and an average price target of $519.28.

Humana Price Performance

Shares of Humana stock opened at $493.91 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 1.53 and a debt-to-equity ratio of 0.73. The firm has a fifty day simple moving average of $487.67 and a 200-day simple moving average of $460.98. The stock has a market capitalization of $62.51 billion, a price-to-earnings ratio of 20.16, a PEG ratio of 1.46 and a beta of 0.77. Humana has a 1-year low of $351.20 and a 1-year high of $514.98.

Humana (NYSE:HUMGet Rating) last released its earnings results on Wednesday, July 27th. The insurance provider reported $8.67 earnings per share for the quarter, topping analysts’ consensus estimates of $7.67 by $1.00. The firm had revenue of $23.66 billion during the quarter, compared to analyst estimates of $23.44 billion. Humana had a net margin of 3.52% and a return on equity of 18.42%. The business’s revenue was up 14.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.89 EPS. On average, sell-side analysts expect that Humana will post 24.97 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Shareholders of record on Friday, September 30th will be paid a $0.7875 dividend. This represents a $3.15 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date is Thursday, September 29th. Humana’s dividend payout ratio is currently 12.86%.

Insider Buying and Selling at Humana

In other Humana news, insider Joseph C. Ventura sold 1,226 shares of the company’s stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $506.78, for a total transaction of $621,312.28. Following the transaction, the insider now directly owns 3,930 shares in the company, valued at approximately $1,991,645.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HUM. Tcwp LLC acquired a new position in Humana in the first quarter valued at about $25,000. Castleview Partners LLC raised its position in shares of Humana by 46,704.0% in the 2nd quarter. Castleview Partners LLC now owns 11,701 shares of the insurance provider’s stock valued at $25,000 after acquiring an additional 11,676 shares during the period. Jones Financial Companies Lllp bought a new position in Humana during the 2nd quarter worth approximately $29,000. WFA of San Diego LLC acquired a new position in Humana during the second quarter valued at approximately $30,000. Finally, Riverview Trust Co bought a new stake in Humana in the first quarter valued at approximately $32,000. Institutional investors and hedge funds own 93.50% of the company’s stock.

About Humana

(Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Stories

The Fly logo

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.